NovaBay Pharmaceuticals Announces the Availability of KN95 Disposable Masks on Avenova.com
March 25 2020 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the availability of KN95 disposable air filter masks on the
Company’s website Avenova.com. The masks are being sold at a price
of $59.99 for a package containing 10 masks or $149.99 for a
package containing 30 masks. KN95-rated masks are effective at
filtering out at least 95% of airborne particles, including
microorganisms, dust, pollen and air pollution.
“In light of the shortage of protective masks, we have tapped
into our global health supplier network to procure and make
available a high-quality, KN95-rated product at the most reasonable
price possible,” said Justin Hall, NovaBay CEO. “We received our
first shipment of KN95 masks last week, which sold out online very
quickly, and expect a second large inventory of masks to be
available for shipment today. To meet the immediate need, we had
the masks flown in on a rush basis. We have direct access to a
large supplier of KN95 masks and encourage organizations ordering
quantities of 50,000 or more to contact us directly at
1-800-890-0329 for special pricing.
“We plan to continue providing KN95 masks on Avenova.com for as
long as the demand remains,” Mr. Hall added. “In these most unusual
of circumstances, it’s gratifying for the NovaBay team to carry out
our commitment to marshal all of our talents and resources to
benefit the health and wellbeing of people everywhere. We will
continue to be here to help accomplish this objective during and
after this crisis is over.”
The NK95 disposable masks are constructed with a three-layer
filtration system of nonwoven soft and breathable fiber for
effective protection. The masks feature extra soft and comfortable
elastic ear loops that will not apply pressure to the ears during
use and have an adjustable nose bridge strip. The masks come in a
single size that fits most faces. They are non-toxic, odorless,
non-irritating, contain no dyes and are hypoallergenic and gentle
on the skin. The disposable masks should be replaced daily for best
hygiene and are ideal for one-time use in a non-medical
setting.
The KN95 air filter masks are manufactured by Earntz Nonwoven
Co., Ltd. and are CE certified for FFP2 protective mask (EN
149-2001) and meet KN95-level requirements (GB 2626-2006).
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market NEUTROPHASE® for wound care market.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our current re-branding strategy,
the launch of a new marketing initiative, and the impact any of
these efforts may have on our future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to consumer acceptance of our new
branding, and any potential damage to our established goodwill in
the marketplace. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings with
the Securities and Exchange Commission, especially under the
heading “Risk Factors.” The forward-looking statements in this
release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s Progress Like us on Facebook Follow
us on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200325005112/en/
NovaBay Contact Justin Hall
CEO and General Counsel 510-899-8800 jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024